Arcus Biosciences Inc
NYSE:RCUS
Arcus Biosciences Inc
NYSE:RCUS
Price:
17.11 USD
-0.58%
Market Closed
Updated:
May 15, 2024
Arcus Biosciences Inc
Operating Expenses
|
Arcus Biosciences Inc
Operating Expenses Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Arcus Biosciences Inc
NYSE:RCUS
|
Operating Expenses
-$487m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$19.5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$12.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$12.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$4.8B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$7.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-19%
|
See Also
What is Arcus Biosciences Inc's Operating Expenses?
Operating Expenses
-487m
USD
-487m
USD
Based on the financial report for Mar 31, 2024, Arcus Biosciences Inc's Operating Expenses amounts to -487m USD.
What is Arcus Biosciences Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-48%
-48%
Over the last year, the Operating Expenses growth was -17%. The average annual Operating Expenses growth rates for Arcus Biosciences Inc have been -24% over the past three years , -48% over the past five years .
You don't have any saved screeners yet
